Physician profile

Shawna Mann

Family · Lexington, KY

NPI 1598320145

$111.09

in general payments reported to CMS, 2019-2025

5 companies · $44.16 in 2025

The $44.16 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$44.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $47.70 2021-2025
Agile Therapeutics, INC. $17.45 2021
Pfizer INC. $16.96 2025
Astellas Pharma US INC $16.03 2021
Exeltis, USA INC. $12.95 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Shawna Mann

$111.09

in general payments reported 2019-2025

Years
2021-2025
Top company
Abbvie INC.
Context
The $44.16 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/10959122/shawna-mann

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.